Epithalon + GHK-Cu Anti-Aging Stack:
Protocol Research Guide

Epithalon: Telomere and Pineal Mechanisms

Epithalon (Ala-Glu-Asp-Gly) is a synthetic tetrapeptide originally derived from the bovine pineal gland by Vladimir Khavinson's group at the Institute of Bioregulation and Gerontology in St. Petersburg. Its primary characterised mechanisms include: activation of telomerase (hTERT) in somatic cells, restoration of melatonin secretion rhythms in aged animals, and upregulation of p53-mediated DNA repair pathways.

The telomerase activation finding is the most cited mechanistic claim. In cell culture studies, Epithalon treatment increases hTERT expression and results in measurable telomere lengthening in human fibroblast lines. In rodent aging models, administration produces improvements in circadian rhythm markers and extends maximum lifespan in some studies, though these results remain to be replicated in long-lived mammal models.

GHK-Cu: Extracellular Matrix and Gene Expression

GHK-Cu (Glycine-Histidine-Lysine complexed with copper(II)) has a substantially larger published literature base than Epithalon, with over 50 peer-reviewed studies spanning skin repair, anti-inflammatory activity, anti-cancer gene expression, and organ protection.

Key characterised mechanisms include: stimulation of collagen I, III, and IV synthesis in dermal fibroblasts; activation of metalloproteinases for remodelling of cross-linked collagen; induction of antioxidant gene expression via Nrf2 pathway activation; and upregulation of VEGF, bFGF, and TGF-beta for angiogenesis and wound healing. Pickart and Margolina (2018) describe GHK-Cu as a "master regulator" of tissue repair gene expression based on transcriptomic analysis.

Synergistic Rationale

The two peptides target non-overlapping biological systems. Epithalon addresses the nuclear/genomic axis — telomere erosion, circadian disruption, and DNA repair capacity decline. GHK-Cu addresses the extracellular/matrix axis — collagen loss, tissue structural integrity, and antioxidant defence. Running them concurrently allows research into whether improvements in one axis (cellular longevity via Epithalon) are potentiated by improvements in the other (tissue environment via GHK-Cu).

Common Research Protocol Designs

Epithalon Cycling (Periodic Dosing)

Epithalon is universally cycled rather than run continuously. Standard research cycles observed in published literature:

• Short cycle: 5–10 mg daily for 10 consecutive days, then 20-day washout
• Annual repetition: 2–3 cycles per year (spring and autumn in some protocols)
• Administration: subcutaneous injection or intranasal (lower bioavailability, less studied)

GHK-Cu Dosing (Continuous or Cycling)

GHK-Cu is commonly run continuously or in longer cycles given its safety profile and rapid clearance:

• Continuous: 1–2 mg daily subcutaneous or topical (skin research)
• Cycling: 2 mg daily, 12 weeks on, 4 weeks off
• Can bridge Epithalon washout periods without interruption

Combined Protocol Example

• Month 1: Epithalon 10mg/day × 10 days + GHK-Cu 1mg/day throughout
• Months 2–3: GHK-Cu only (1–2mg/day) during Epithalon washout
• Month 4: Repeat Epithalon cycle + continue GHK-Cu
• Months 5–6: GHK-Cu maintenance, optional Thymosin Alpha-1 addition

Extension: Thymosin Alpha-1 Addition

The intermediate Anti-Aging Stack adds Thymosin Alpha-1 (1.5 mg twice weekly) to address the third axis of aging: immune senescence. Thymic involution and the associated loss of naive T-cell output is a central feature of immunological aging. Thymosin Alpha-1 has the most extensive clinical literature of the three compounds, having been used in hepatitis B/C treatment in multiple Asian markets.